Huafeng Xu, Ph.D.

Chief Technology Officer

Huafeng Xu Portrait

As chief technology officer, Huafeng oversees the development of new computational methods and models in the Roivant Discovery platform. He also provides guidance on their applications in drug discovery projects. Huafeng joined Silicon Therapeutics prior to its acquisition by Roivant Sciences. 

Previously, Huafeng spent 12 years at D. E. Shaw Research, a privately held biochemistry research company based in New York, where he played an early role in the design of the specialized Anton chip for molecular dynamics simulations and led development of the methods and software for free energy calculations that are now widely used in the pharmaceutical industry.  His research interests include development of simulation methods, free energy calculations, structural immunology, protein folding and misfolding and molecular design.

Huafeng earned a bachelor of science degree in chemistry from Peking University in Beijing, China and a master of science and a doctor of philosophy degree in chemical physics from Columbia University in New York.

Follow Huafeng: